Skip to main content
Study finds empagliflozin improves CV outcomes in diabetes

Researchers conducted a post hoc analysis of the EMPA-REG OUTCOME trial involving 5,973 type 2 patients with diabetes patients and with or without left ventricular hypertrophy and found that those who received 10 mg or 25 mg daily of empagliflozin had a reduced risk for all-cause mortality and cardiovascular death and fewer three-point major adverse CV events than those on placebo. The findings were published in Diabetes Care.

Full Story: